Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?
Eurofins BioPharma Product Testing
As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support. More info >>
Registration is now open for the flagship conference, OCT
New England which will return to Boston this September. Following the
tremendous success of the 2016 event, the OCT team have been busy putting
together the most content driven, high quality agenda to date. The speaker
line-up is the best so far, with senior professionals from across the field
currently finalizing their interactive presentations and sessions. More info >>
